NASDAQ:CNSTConstellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNST stock has decreased by 11.5% and is now trading at $28.83. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Constellation Pharmaceuticals.

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Constellation Pharmaceuticals.

Constellation Pharmaceuticals Inc (NASDAQ:CNST) issued its earnings results on Wednesday, May, 6th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.62) by $0.01. View Constellation Pharmaceuticals' earnings history.

9 equities research analysts have issued twelve-month price targets for Constellation Pharmaceuticals' stock. Their forecasts range from $34.00 to $75.00. On average, they expect Constellation Pharmaceuticals' share price to reach $48.38 in the next twelve months. This suggests a possible upside of 67.8% from the stock's current price. View analysts' price targets for Constellation Pharmaceuticals.

News coverage about CNST stock has been trending somewhat negative on Friday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Constellation Pharmaceuticals.

Constellation Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 1,570,000 shares, an increase of 37.7% from the May 31st total of 1,140,000 shares. Based on an average daily trading volume, of 443,600 shares, the short-interest ratio is presently 3.5 days. Currently, 6.1% of the company's shares are sold short. View Constellation Pharmaceuticals' Current Options Chain.

Some companies that are related to Constellation Pharmaceuticals include Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Myokardia (MYOK), Emergent Biosolutions (EBS), Global Blood Therapeutics (GBT), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN), Nektar Therapeutics (NKTR), Evotec (EVTCY), Amicus Therapeutics (FOLD), GW Pharmaceuticals PLC- (GWPH), Agios Pharmaceuticals (AGIO), FibroGen (FGEN), HUTCHISON CHINA/S (HCM) and BridgeBio Pharma (BBIO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Axsome Therapeutics (AXSM), AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Crispr Therapeutics (CRSP), Enphase Energy (ENPH), Novavax (NVAX), NVIDIA (NVDA) and Provention Bio (PRVB).

(CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $28.83.

Constellation Pharmaceuticals has a market capitalization of $1.21 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]